October 24, 2014 12:08 PM ET

Capital Markets

Company Overview of ChrysCapital

Company Overview

ChrysCapital is a private equity and venture capital firm specializing in management buy-outs or buy-ins, co-investments, public equity, PIPEs, growth capital in private and listed companies, and special situations including carve outs, joint ventures. The firm focuses on the business services; information technology; consumer goods and services; financial services; real estate; healthcare with a focus on pharmaceuticals, medical diagnostics and devices; infrastructure, power, and manufacturing sectors. It makes investments in companies based in or focusing on India and United States. The firm invests between $10 million and $300 million in companies with revenues ranging between $50 million...

Dr. Zakir Hussain Marg

The Oberoi

Suite 101

New Delhi,  110 003

India

Founded in 1999

Phone:

91 11 5129 1000

Fax:

91 11 5129 1010

Key Executives for ChrysCapital

Group Manager
Managing Director and Chief Financial Officer
Managing Director
Managing Director
Age: 37
Managing Director and Managing Partner
Age: 56
Compensation as of Fiscal Year 2014.

ChrysCapital Key Developments

ChrysCapital Reportedly In Talks To Sell Mankind Pharma

ChrysCapital intends to sell its stake in Mankind Pharma Limited. ChrysCapital is holding talks to sell its 11% stake in Mankind Pharma. The potential buyers are all PE firms, including Temasek Holdings (Private) Limited, General Atlantic LLC, Actis Capital, LLP and Advent International Corporation. ChrysCapital hopes to fetch over $200 million for its 11% holding. Financial Services Monitor Worldwide added that Ramesh Juneja, Chief Executive Officer of Mankind, said in an email response: Regarding ChrysCapital seeking exit from Mankind you may directly speak with them because it is entirely their decision. ChrysCapital spokesperson Sanjiv Kaul declined comment.

Chryscapital-GIC Team Emerges As Front-Runner In Race To Buy Destimoney

A consortium of ChrysCapital and GIC Pte. Ltd. has emerged as the front-runner to purchase New Silk Route's (NSR) 100% stake in Destimoney Enterprises Private Limited. "They seem to have gained a clear edge over rival bidders", said a person directly involved with the transaction. The deal may value the company between INR 10 billion and INR 11 billion. NSR has mandated Morgan Stanley to sell Destimoney. Actis Capital, LLP and General Atlantic LLC had also participated in the bidding. While New Silk Route's Chief Executive Officer Parag Saxena did not reply to email questions on the subject, Destimoney's Managing Director and Chief Executive Officer Sudip Bandyopadhay declined comment.

ChrysCapital Presents at SuperReturn Emerging Markets 2014, Jun-26-2014 11:20 AM

ChrysCapital Presents at SuperReturn Emerging Markets 2014, Jun-26-2014 11:20 AM. Venue: The Okura Hotel, Amsterdam, Netherlands. Speakers: Gulpreet Kohli, Managing Director.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 2, 2014
Intas Pharmaceuticals Ltd.
Private Placement
April 15, 2014
Au FINANCIERS (INDIA) LIMITED
Private Placement
April 3, 2014
Torrent Pharmaceuticals Ltd.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ChrysCapital, please visit www.chryscapital.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.